Brokerages expect Kadmon Holdings Inc (NYSE:KDMN) to report $560,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Kadmon’s earnings. The highest sales estimate is $1.04 million and the lowest is $150,000.00. Kadmon posted sales of $2.28 million in the same quarter last year, which would indicate a negative year over year growth rate of 75.4%. The firm is scheduled to issue its next quarterly earnings report on Thursday, November 8th.
According to Zacks, analysts expect that Kadmon will report full-year sales of $2.45 million for the current year, with estimates ranging from $1.04 million to $3.60 million. For the next fiscal year, analysts anticipate that the company will report sales of $41.21 million, with estimates ranging from $600,000.00 to $115.64 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Kadmon.
Kadmon (NYSE:KDMN) last released its quarterly earnings data on Thursday, August 9th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.50. The company had revenue of $0.36 million during the quarter, compared to analyst estimates of $0.90 million.
A number of institutional investors have recently modified their holdings of KDMN. Vivo Capital LLC increased its holdings in Kadmon by 213.6% in the second quarter. Vivo Capital LLC now owns 10,454,545 shares of the company’s stock valued at $68,919,000 after buying an additional 7,121,212 shares in the last quarter. BlackRock Inc. increased its holdings in Kadmon by 209.3% in the second quarter. BlackRock Inc. now owns 4,763,436 shares of the company’s stock valued at $19,005,000 after buying an additional 3,223,211 shares in the last quarter. Acuta Capital Partners LLC increased its holdings in Kadmon by 52.3% in the second quarter. Acuta Capital Partners LLC now owns 9,060,014 shares of the company’s stock valued at $36,149,000 after buying an additional 3,110,014 shares in the last quarter. Millennium Management LLC increased its holdings in Kadmon by 490.1% in the first quarter. Millennium Management LLC now owns 1,847,444 shares of the company’s stock valued at $7,852,000 after buying an additional 1,534,371 shares in the last quarter. Finally, VHCP Management II LLC purchased a new position in Kadmon in the second quarter valued at about $5,632,000. 69.66% of the stock is owned by institutional investors.
NYSE KDMN traded down $0.13 during trading hours on Monday, hitting $2.61. The company had a trading volume of 710,994 shares, compared to its average volume of 865,497. Kadmon has a 1-year low of $2.60 and a 1-year high of $5.86. The company has a market capitalization of $309.90 million, a PE ratio of -1.84 and a beta of 3.63.
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes a portfolio of branded generic ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Read More: How analysts view the yield curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.